What this system does.
The Lineage — Thousands of Years of Human Evidence
The archaeological and anthropological record of human relationship with plant medicines is extensive. Psilocybin mushroom use in Mesoamerica is documented in stone carvings dating to 3,000 BCE; the Aztec called them teonanacatl — 'flesh of the gods' — and used them in healing ceremonies preserved through the Mazatec tradition into the present. The Eleusinian Mysteries of ancient Greece — attended by Plato, Aristotle, Sophocles, and Cicero among thousands of others — appear to have centered on a psychoactive preparation (kykeon) made from ergot-infected barley, described by participants as producing the most significant experience of their lives. Ayahuasca traditions in the Amazon predate Western contact by millennia — preserved in living Shipibo, Huni Kuin, and Santo Daime traditions today. The San Pedro cactus has been used ceremonially on the Peruvian coast for at least 3,500 years. Iboga in the Bwiti tradition of Gabon is a complete initiatory healing system. What all of these traditions share: ceremonial container, intention, preparation, experienced facilitation, and integration of the experience into life. The set and setting insight of modern research is ancient wisdom.
How These Compounds Work — The Mechanisms
Psilocybin (converted to psilocin in the body) binds primarily to 5-HT2A serotonin receptors, concentrated heavily in the prefrontal cortex — producing the characteristic disruption of the Default Mode Network (the self-referential, ruminative brain network) and a state of heightened connectivity between brain regions that normally do not communicate. Robin Carhart-Harris's REBUS model (Relaxed Beliefs Under Psychedelics) frames this as a temporary reduction in top-down predictive processing — allowing experience to arrive unfiltered by the accumulated prior beliefs that normally shape perception. MDMA produces a synchronized release of serotonin, dopamine, and oxytocin — creating a state of emotional openness, reduced fear response, and heightened social trust that makes trauma processing possible without retraumatization. Ketamine (NMDA receptor antagonism) produces a rapid glutamate surge followed by BDNF release and synaptogenesis — the most rapid antidepressant mechanism yet identified, producing measurable mood effects within hours. Ayahuasca (DMT + MAOI harmalines) activates 5-HT2A receptors and sigma-1 receptors — with documented effects on neuroplasticity and hippocampal neurogenesis in animal models. Ibogaine resets the opioid receptor system and produces a long-duration dreamlike state associated with trauma processing and addiction interruption. Different mechanisms. Convergent outcomes.
Neuroplasticity Reset — The Unifying Biology
Across compounds and across traditions, a consistent neurobiological theme has emerged in the past decade of mechanistic research: psychedelics are neuroplasticity catalysts. They promote synaptogenesis (formation of new synaptic connections), increase BDNF, activate TrkB receptors, and produce measurable structural brain changes after even a single dose. David Olson at UC Davis coined the term 'psychoplastogen' for this class of compounds — substances that rapidly promote structural neural plasticity. The therapeutic window hypothesis: the neuroplastic window opened by a psychedelic experience creates a period of enhanced learning and restructuring, during which therapeutic work and integration practices can produce changes that would otherwise require months or years of standard approaches. This is not magic — it is molecular biology. The same BDNF-TrkB pathway that exercise, sleep, and meditation build, psychedelics activate with unusual speed and intensity.
Deficiency signals.
This section is different from other system pages. It is not about physiological deficiency in the conventional sense. It is about the conditions that lineage traditions and modern clinical research have consistently identified as responsive to psychedelic healing work.
- Treatment-resistant depression — low or absent response to conventional antidepressants after adequate trials
- PTSD and complex trauma that has not responded to standard therapy approaches
- End-of-life existential distress — fear of death, loss of meaning, existential despair in terminal illness
- Addiction and substance dependence — particularly alcohol, opioids, and tobacco in the research literature
- Profound disconnection — from self, from others, from nature, from meaning — that does not respond to conventional approaches
- Grief that has become stuck rather than moving through
- Major depression with features of anhedonia — the inability to experience pleasure or meaning
- Existential emptiness — a life that functions adequately but lacks felt meaning or purpose
- Chronic patterns that persist despite sincere effort to change — behaviors, beliefs, relational dynamics that feel immovable
- Spiritual emergency or awakening without adequate container or understanding
- The sense of fundamental separation — from the natural world, from other humans, from something larger than the individual self
- Creative or vocational stagnation — loss of the generative vision that once animated the work
- Burnout at the level of purpose, not just energy — when the work is done but the why has gone silent
- The felt absence of wonder — the flattening of experience that follows chronic stress, trauma, or long adaptation to survival mode
Indigenous traditions did not limit plant medicine to pathology. Ceremony was woven into the fabric of community life — for initiation, for seasonal transitions, for community healing, for connection to the natural world. The clinical research is recovering these applications one condition at a time. The lineage held them whole.
Toxicity signals.
Contraindications — Who Should Not Use These Medicines
Psychedelic substances are powerful and not appropriate for everyone. Clear contraindications supported by research and clinical consensus: personal or family history of psychosis, schizophrenia, or bipolar disorder with psychotic features (5-HT2A agonism can precipitate psychotic episodes in vulnerable individuals). Concurrent lithium use with classic psychedelics significantly increases seizure risk. SSRI and SNRI medications reduce the effects of psilocybin and LSD through receptor competition, and carry serotonin syndrome risk in combination with MDMA. Cardiovascular conditions require careful screening, particularly for MDMA and stimulant-like compounds. Pregnancy. These contraindications are not reasons to dismiss the medicine — they are reasons to work with qualified professionals who can screen appropriately and provide the container that transforms a potentially difficult experience into a healing one.
The Criminalization Interruption — Understanding What Was Lost
The Controlled Substances Act of 1970 in the United States classified psilocybin, LSD, MDMA, and DMT as Schedule I — defined as having no accepted medical use and high abuse potential. This classification was not based on medical evidence. It occurred in the context of the Nixon administration's explicit campaign against the counterculture and anti-war movement — documented years later in the admission of Nixon aide John Ehrlichman. Over 1,000 studies had been conducted on LSD and psilocybin between 1950 and 1970, with promising findings in addiction, end-of-life care, and depression. All of this research was halted for decades. The research renaissance beginning in the 2000s at Johns Hopkins, NYU, Imperial College London, MAPS, and others is not a new discovery — it is the resumption of interrupted medicine.
Set, Setting, and Integration — What the Research Consistently Confirms
The most important variable in psychedelic experience outcomes is not the compound — it is the context. Set (mindset, intention, preparation, psychological state) and setting (physical environment, safety, presence of skilled facilitators) determine whether a powerful experience becomes healing or destabilizing. This is not a modern insight — it is the foundational design principle of every lineage tradition: the ceremony, the preparation, the role of the curandero, the healer, the guide. Modern clinical research has operationalized this as therapeutic alliance, preparatory sessions, and integration work following the experience. Integration — the process of making meaning from the experience and embodying its insights in daily life — is widely considered as important as the experience itself. The window of enhanced neuroplasticity that opens after the experience is the opportunity. Integration is how the opportunity becomes lasting change.
The Cellular Six connection.
Psychedelics produce the most radical alteration of the Sense function available through any known input — temporarily dissolving the predictive filters that normally shape raw perception into a coherent and familiar world. The 5-HT2A receptor activation in sensory and prefrontal cortices produces synesthesia, heightened pattern recognition, dissolution of the figure-ground boundary between self and world, and the mystical experience of unity that William James identified as the core of genuine religious experience across traditions. This is not noise in the Sense system — it is a different mode of operation, one in which experience arrives less filtered, more immediate, more alive.
The gut-brain axis exchanges with psychedelic states through the same serotonin system that mediates the central effects — 5-HT2A and 5-HT3 receptors are abundant in the enteric nervous system, which is why nausea is common with psilocybin and ayahuasca (particularly ayahuasca, which also inhibits MAO, slowing the breakdown of gut serotonin). Indigenous preparations consistently include purging protocols as part of the ceremony — not incidentally but intentionally, understood as part of the cleansing process. The microbiome research on psychedelics is in its earliest stages, but the mechanistic connection is well-established: these are not brain-only compounds.
The rapid antidepressant effect of ketamine — and the emerging rapid antidepressant evidence for psilocybin — operates through a Transform mechanism: NMDA antagonism or 5-HT2A agonism produces a glutamate surge, BDNF release, and synaptogenesis within hours. This is the fastest known biological Transform of mood-relevant neural architecture. For treatment-resistant depression, where conventional approaches produce change on timescales of weeks if at all, this rapid Transform mechanism represents a qualitatively different category of intervention.
Synaptogenesis — the formation of new synaptic connections — is the BUILD mechanism through which psychedelic experiences become lasting change at the cellular level. Olson's psychoplastogen research documents that psilocin, DMT, and related compounds promote dendritic growth and spine density at concentrations far below those required for behavioral effects in animal models. The therapeutic window hypothesis rests on this BUILD mechanism: the structural neural changes initiated during or shortly after the psychedelic experience create the substrate for new patterns to consolidate.
The inflammation-MAINTAIN connection for psychedelics is mechanistically documented but clinically early. Psilocin activates 5-HT2A receptors on microglia (the brain's immune cells) and has been shown to reduce neuroinflammatory signaling in cell studies. The anti-inflammatory effects of psychedelics may be one mechanism underlying their efficacy in depression — which is increasingly understood as a neuroinflammatory condition in a significant subgroup of patients. More research is needed; the mechanism is plausible and the preliminary evidence is promising.
The defining feature of a genuinely transformative psychedelic experience is the dissolution of fixed self-concept — the rigid, habitual patterns of thought, belief, and identity that maintain suffering by remaining unexamined. Carhart-Harris's REBUS model frames this as a temporary reduction in the precision of prior beliefs — allowing the system to re-weight experience against an open prior rather than a fixed one. This is the ADAPT function at its most fundamental: the loosening of rigid adaptation into flexible re-adaptation. The clinical outcomes — reduction in experiential avoidance, increased psychological flexibility, increased connection to values and meaning — map precisely onto the Adapt function's healthiest expression.
Learn more about The Cellular Six →
How this system connects to the others.
Psychedelics connect to the rest of this site through the systems they most profoundly affect. The neuroplasticity mechanism places this page in direct dialogue with /neuroplasticity — psychedelics are the most rapid known neuroplasticity catalysts.
Read moreShow less
The trauma resolution outcomes connect directly to /trauma — MDMA-assisted therapy and psilocybin-assisted therapy are the most effective interventions yet documented for treatment-resistant PTSD and trauma. The Default Mode Network disruption and present-moment access connect to /mindfulness — many long-term meditators describe psychedelic experiences as confirming and deepening their contemplative practice. The gut-serotonin connection links to /gut-health. The BDNF and synaptogenesis mechanism connects to /movement and /sleep — the same molecular pathway, activated differently. And the meaning dimension — the consistent finding that psilocybin experiences produce lasting increases in felt purpose, connection, and openness — connects this page to every MEANING system page that follows.
Neuroplasticity
the most rapid known neuroplasticity catalysts
Trauma & Inner Work
the most effective documented interventions for treatment-resistant PTSD
Mindfulness & Meditation
DMN disruption and present-moment access
Purpose & Legacy
psilocybin experiences and lasting increases in felt purpose
Faith & Spirituality
the pharmacological induction of mystical-type experience
Gut Health
the gut-serotonin connection
What to measure.
Psychological Flexibility and Experiential Avoidance
What: Acceptance and Action Questionnaire (AAQ-II) — validated 7-item measure of psychological flexibility and experiential avoidance; available free online. Why: Psychological flexibility — the capacity to be present with difficult experience rather than avoiding it — is the core therapeutic mechanism targeted by both psychedelic experiences and ACT therapy. Measuring it before and after an experience reveals whether the work is producing the fundamental shift it aims for. Where: Free download at contextualscience.org; self-administered in 2 minutes.
Connectedness to Nature and Meaning
What: Connectedness to Nature Scale (Nisbet et al.) and Meaning in Life Questionnaire (MLQ, Steger et al.) — both validated, free, and brief. Why: These are the two outcome domains most consistently associated with positive psychedelic experiences in the Johns Hopkins research — increased connection to the natural world and to a sense of personal meaning. Tracking them before and after reveals the experiential territory that has shifted.
HRV and Inflammatory Markers — The Biological Correlates
What: Resting HRV (daily wearable tracking), hsCRP and IL-6 at baseline and 4-8 weeks after. Why: The neuroplastic and anti-inflammatory mechanisms documented in research produce measurable biological signals. Ketamine's rapid antidepressant effect is associated with BDNF elevation measurable in serum within 24 hours. HRV improvement reflects autonomic flexibility restored after trauma-pattern release. These provide objective grounding for subjective experiences of change.
Practice first, then targeted support.
The non-negotiables — what the lineage and the research agree on:
- Intention: entering any experience with a clear, sincere intention — not a demand for a specific outcome but an honest statement of what you are bringing and what you are seeking. Intention shapes the direction of the work.
- Preparation: the weeks before a significant experience matter as much as the experience itself. Reducing alcohol, processed food, and recreational drug use. Increasing meditation, time in nature, journaling, and therapeutic work. Reviewing your intention. Telling the people who love you what you are doing and why.
- Set and setting: physical safety, emotional safety, trust in your facilitator or guide, a space that feels sacred — not clinical, not recreational. The experience will meet you where you are. Prepare the meeting place.
- Skilled facilitation: for any significant work, the presence of an experienced, trained facilitator — whether a licensed clinician, a traditional curandero, or a trained guide — is the most important safety variable available.
- Integration: after the experience, the work begins. Journaling. Therapeutic processing. Sharing with trusted community. Somatic practices to embody insights. Meditation to maintain the open window. Movement to support the neuroplastic integration. The insight without integration is a beautiful dream you wake from unchanged.
Legal and clinical pathways currently available:
- Ketamine-assisted therapy: legal, available through licensed ketamine clinics throughout the US and internationally. The most clinically accessible psychedelic medicine currently available.
- Psilocybin therapy: legal in Oregon and Colorado through state-licensed facilitation programs; available in the Netherlands, Jamaica, and Mexico in legal retreat settings. Clinical trials ongoing at Johns Hopkins, NYU, UCSF, and others.
- MDMA-assisted therapy: Phase 3 trial data published (Mitchell et al. 2021); FDA decision pending. Currently available through clinical trials for PTSD; international availability varies.
- Ayahuasca: legal in Peru, Brazil, and various other countries; Shipibo and Santo Daime retreats offer traditional ceremonial contexts.
- Ibogaine: legal in Mexico, New Zealand, South Africa, and others — significant research base for opioid use disorder; cardiac screening essential due to QT interval prolongation.
Nutritional support is for the integration period — supporting the neuroplastic window that opens after an experience.
- Omega-3 DHA/EPA (2-3g/day): Structural support for synaptogenesis — DHA is a primary component of the new synaptic membranes being formed during the neuroplastic window. The most important nutritional input for the BUILD phase after an experience.
- Magnesium-L-threonate (1.5-2g/day): Brain magnesium elevation supports NMDA receptor modulation and the synaptic consolidation occurring in the integration window.
- Lion's Mane mushroom (500-1000mg standardized): NGF support for the cholinergic neurons most involved in memory consolidation and learning during the integration period.
- B vitamin complex (methylated): Neurotransmitter synthesis support — serotonin, dopamine, and acetylcholine pathways all require B vitamin cofactors and are highly active during and after significant psychedelic experiences.
- Avoid SSRIs/SNRIs for at least 2 weeks after classic psychedelics: these reduce 5-HT2A receptor sensitivity and may blunt or prevent integration of gains. Discuss with prescribing physician before any changes.
- Prioritize sleep, movement, and meditation in the weeks following: the neuroplastic window is open — these are the inputs that determine what grows in it.
The research behind this system.
Griffiths RR et al. (2016)
"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial". Journal of Psychopharmacology.
Finding: Double-blind crossover RCT at Johns Hopkins documented that a single high-dose psilocybin session produced substantial, sustained reductions in cancer-related depression and anxiety at 6-month follow-up — with 80% of participants rating the experience among the five most meaningful of their lives, and mystical experience ratings predicting therapeutic outcome.
Mitchell JM et al. (2021)
"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study". Nature Medicine.
Finding: Phase 3 RCT of MDMA-assisted therapy for treatment-resistant PTSD documented 67% response rate (no longer meeting PTSD diagnostic criteria) vs. 32% in placebo with therapy — the strongest efficacy data in treatment-resistant PTSD in the history of the condition.
Carhart-Harris R et al. (2021)
"Trial of psilocybin versus escitalopram for depression". New England Journal of Medicine.
Finding: Randomized trial comparing psilocybin (two doses) to escitalopram (6-week course) for major depression found equivalent primary outcome scores with psilocybin showing significant advantages on secondary measures including emotional blunting, wellbeing, anhedonia, and psychological connectedness — while escitalopram showed advantages only in anxiety subscales.
Olson DE et al. (2018)
"Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics". Journal of Experimental Neuroscience.
Finding: Foundational paper establishing the psychoplastogen concept — documenting that psilocin, DMT, and related compounds promote structural neural plasticity (dendritic growth, spine density, synaptogenesis) at sub-behavioral doses through TrkB receptor activation — providing the mechanistic framework connecting psychedelic experiences to lasting neurological change.
Ratsch C. (2005)
"The Encyclopedia of Psychoactive Plants: Ethnopharmacology and Its Applications". Park Street Press.
Finding: Comprehensive anthropological and botanical documentation of psychoactive plant use across more than 400 species and virtually every indigenous culture globally — establishing that human use of plant medicines for healing, spiritual, and ceremonial purposes is among the most universal and ancient practices in human history, predating written records by millennia.
Related reading
Articles that go deeper on Psychedelics.
Psychedelics are a class of substances that some traditions and researchers explore for their effects on consciousness, perception, and inner experience. This page presents the topic as education and honest information, including the serious legal, safety, and health considerations involved. It is not advice, encouragement, or instruction to use any substance. This page is educational and is not medical advice.
Common questions
What are psychedelics?+
Psychedelics are a class of substances known for altering consciousness, perception, and inner experience. They have long histories in various traditional and ceremonial contexts and are currently a subject of renewed scientific study.
Why is there renewed research interest?+
Researchers are studying how certain psychedelics affect the brain, consciousness, and mental wellbeing under controlled conditions. This is an active and evolving area of science, and findings are still developing rather than settled.
Are psychedelics legal and safe?+
Legal status varies widely by substance and location, and many remain illegal in many places. There are also real safety, health, and psychological considerations. This page is educational only and does not encourage or instruct anyone to use any substance.
How does this page approach the topic?+
It approaches psychedelics as a subject to understand honestly — history, current research, and the serious legal and safety questions involved — rather than as something to promote. Any decisions belong with qualified professionals and the law where you live.